On June 24, Kelun-Biotech rose 7.44% in regular trading, trading at 428.8 HKD/share, with turnover of HKD 211 million.

On the news front, Kelun-Biotech recently delivered an oral presentation at the ASCO Annual Meeting reporting results from the Phase III OptiTROP-Lung05 study of sac-TMT combined with Keytruda as first-line treatment for PD-L1 TPS≥1% non-small cell lung cancer (NSCLC). The trial randomized 413 patients in a 1:1 ratio to receive either sac-TMT plus Keytruda or Keytruda monotherapy. Xingye Securities initiated coverage with an Overweight rating, noting that sac-TMT has demonstrated best-in-class potential globally and is approaching the overseas commercialization stage in partnership with Merck. The brokerage forecasts revenue of RMB 3.587 billion, RMB 4.355 billion, and RMB 6.712 billion over the next three years, with net profit of RMB 75 million, RMB 498 million, and RMB 1.434 billion, respectively.

The broader Biotechnology sector also strengthened, with AKESO up 2.87%, Innovent Bio up 3.33%, BeiGene up 3.36%, 3SBio up 2.5%, and Remegen up 3.14%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)